# DESCRIPTION

## FIELD OF THE DISCLOSURE

- define VEGF inhibitors

## BACKGROUND OF THE DISCLOSURE

- limitations of current anti-angiogenic strategies

## SUMMARY

- introduce compound of formula (I)

### and R5 is H,

- application of compound of formula (I)

## DETAILED DESCRIPTION OF THE DISCLOSURE

- introduce novel VEGF-A165/NRP-1 inhibitors

### Compounds of the Disclosure

- define compound of formula (I)
- specify groups R1, R2, R4, R5, and A
- describe embodiments of compound of formula (I)
- define subfamilies of compounds (I-A1) and (I-A2)
- introduce isomeric form of compound of formula (I)
- define compounds of formula (I)
- describe binding properties to NRP-1
- define VEGF-A165 and NRP-1
- describe structural features of compounds of formula (I)
- describe proline analogues and their role
- describe embodiments of compounds of formula (I)

### Methods for Preparing Compounds of Formula (I)

- define first preparation method
- outline steps for first preparation method
- define second preparation method
- outline steps for second preparation method
- describe purification and lyophilization

### Pharmaceutical Compositions

- describe pharmaceutical composition and its uses

### Therapeutic Uses

- define therapeutic uses of compound
- specify diseases involving VEGF-A165/NRP-1 interaction
- describe cancer treatment
- define subject and cancer terms
- outline methods for preventing or treating diseases
- describe administration routes and formulations

## EXAMPLES

### Example

- describe synthesis of peptide VEGF-A165/NRP-1 inhibitors
- outline solid phase synthesis of peptides of formula (I)
- detail example 2: solid phase synthesis of compound of formula (I) H-Cys-Lys(hArg)-Dab-ΔPro-Arg
- describe example 3: solid phase synthesis of compound of formula (I) H-Lys(Cys-hArg)-Dab-ΔPro-Arg
- outline washing and cleavage of peptidyl-resin
- describe purification of crude peptide by HPLC
- detail example 4: binding of compounds of formula (I) to NRP-1
- present results of NRP-1 binding assay

